Nicholas Saraceno, Senior Editor

Momentum from the previous two years will propel the sector into the rest of 2024, says AM Best analysis.

The purchase boosts the parties’ sterile liquid manufacturing capabilities.

A JAMA Network Open study dives into how the utilization of a digital patient portal changed during the COVID-19 pandemic, while also exploring ways that multimorbidity and socioeconomic disparities affected those statistics.

The offering reportedly helps avoid product quarantine.

A cohort study investigates a potential correlation between the stresses caused by Mother Nature and mental health.

IPX203—an oral formulation carbidopa/levodopa extended-release capsules —would expand Zambon’s neurology portfolio.

Rob Besse offers a breakdown of the third-party logistics (3PL) process, including lessons that these providers have learned coming out of the pandemic.

A Carrum Health/PWC report surveys benefit managers spanning various self-insured employers in an effort to determine ways to improve the cancer treatment experience, especially from a cost perspective.

An MDVIP study reports that 61% of people feel hassled by the current structure.

An investigation evaluates whether SNAP benefits can also influence hypertension patients’ lack of medication adherence.

Current production of Qdenga will increase to 50 million doses a year.

A cohort study explores the association of Medicare Advantage enrollment with post-acute care use, along with patient outcomes among retired state employees.

The company’s cloud technology services aim to assist healthcare and pharma with AI integration.

A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.

The CRO’s FortreaRx doubles in size, including a boost in cold chain storage, while also continuing to improve its patient access services.

The annual report published by IQVIA examines movement surrounding drug launches and new clinical trials, during the post-pandemic era.

A cohort study investigates how a change in clinical guidelines, an expanded label, and reduction in drug prices can impact the use of PCSK9 inhibitors as a treatment for atherosclerotic cardiovascular disease.

OneScan 7.1 is expected to boost compliance, while also improving pharma supply chain efficiencies.

A trial set out to determine whether empagliflozin can help prevent hospitalizations and extend life for patients with heart failure, while not hurting the US payers’ pockets.

Phase III results from Keytruda (pembrolizumab)’s NRG-GY018 trial help influence the agency’s decision.

Arshad M. Khanani, MD, MA, FASRS, will help lead development efforts for sozinibercept, a potential wet AMD treatment.

As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.

The agency will make its final decision surrounding the locally advanced or metastatic nonsquamous NSCLC drug —based on results from the TROPION-Lung01 Phase III trial—by Q4 2024.

The partnership revolves around meeting various agency standards and industry requirements pertaining to the drug development and manufacturing lifecycle.

The new seals include sustainable film material containing recyclate content of up to 90%.

The financial commitment features construction of new warehouses in Pennsylvania and North Carolina.

Scientists develop algorithms that can not only identify tumors that will respond well to chemotherapy, but which are also likely to resist treatment.

Analysis explores where drug prices are derived from, and whether a holistic societal approach can help determine these products’ true value.

Examination evaluates investigational stem cell interventions, including how the states have implemented their own policies when it comes to their uses.

Cohort study explores value-based insurance designs, while also determining how one’s place of residency can potentially play a role.